COMFORT-1 and joy for Incyte/Novartis' JAK inhibitor
This article was originally published in Scrip
Executive Summary
Incyte will file for approval of its leading oral dual JAK inhibitor INCB18424 (ruxolitinib/INC424) for myelofibrosis in the US in the second quarter of 2011, based on highly promising results from its first Phase III study, COMFORT-1. It hopes the drug will become the first FDA-approved drug to treat the debilitating symptoms of the disease.